Adults newly diagnosed with narcolepsy type 1 rack up healthcare costs 5.5 times higher than people without the condition, a ...

Federal HIV guidelines add Bixlenvo as a switch option, back statins for adults 40 to 75 and urge clinicians to challenge payer barriers to antiretroviral therapy (ART).

Sempre Health works with health plans, pharmacy benefit managers (PBMs), drugmakers and patients to lower out-of-pocket costs. Mathur is co-presenting “The Last Mile at Point-of ...

Adam Colborn, vice president of government affairs at AMCP, said the Consolidated Appropriations Act of 2026 (CAA), signed ...

Calling intismeran a cancer vaccine is catchy and makes some sense, but it lacks precision. Moderna and Merck are describing ...

Christine Johnston says biosimilar interchangeability bills, plus 2026 PBM reforms, would force PBMs to justify preferring higher-cost brands. Proposed legislation that would make approved biosimilars ...

Chad Hatfield, Pharm.D., of UC Davis Health, says 340B savings fund free clinics and mental health care that could shrink as the program’s future shifts. The future of the 340B Drug Pricing Program ...

A Cencora analysis of 32 pre-approval products found more than 60% of payer engagement with PIE resources came more than 90 ...

Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.

Ty Gluckman, M.D., says the 2026 dyslipidemia guideline brings back risk-based LDL goals, and clinical inertia, not access, ...

Ty Gluckman, M.D., says undertesting and undertreatment are the biggest gaps in lipid care and calls on leaders to invest in ...

Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B ...